Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotechnology company in clinical phase that is developing the drug candidate arfolitixorin that aims to increase the efficacy of standard treatments for patients with severe forms of cancer.
Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s shares are traded on Nasdaq Stockholm.
Latest press releases
2026-11-04
Biostock Life Science Summit 2026
Isofol participated in Biostock Life Science Summit 2026 during November. CEO, Petter Segelman Lindqvist, provided an update on the company and the ongoing clinical phase Ib/II study.
2026-09-22
Biostock Investing in Life Science
Isofol participated in Biostock’s Investing in Life Science where CEO, Petter Segelman Lindvist, gave an update on the company and the ongoing clinical study with the drug candidate arfolitixorin in patients with metastatic colorectal cancer.
2026-08-25
Interim report Q2 2026
”The second quarter of 2026 was characterized by a continued strong focus on advancing the clinical development of our drug candidate arfolitixorin toward becoming a new cornerstone of cancer treatment. During the quarter, we placed additional emphasis on optimizing the study design and accelerating patient recruitment. With a newly opened investigational site in Germany in the third quarter and approval from the Safety Review Committee to initiate the highest dose-escalation cohort of 500 mg/m2, we are shifting into a higher gear as we advance toward the phase II part of the study.” says CEO, Petter Segelman Lindqvist.
For investors
Upcoming Events
- Isofol invites investors, shareholders and other stakeholders to an Investor & Scientific Update in Stockholm on November 12. An investor meeting will be held in Gothenburg on November 13 to present and discuss the key messages from the Stockholm meeting.
Latest reports and presentations
